



# Nexus AG: Strong Sales and Earnings Increase in the First Quarter 2021

Donaueschingen, 11 May 2021: Nexus AG, one of the leading European suppliers of software solutions in the healthcare sector, was able to increase its sales by 13.0% and earnings before taxes (EBT) by 18.2% in the first three months of 2021. As a result, the continually positive development of sales and earnings of the last years could be continued.

Sales improved from KEUR 38,870 to KEUR 43,940 (+13.0%). In the first three months. The international share of total business volume was 47.2% (3M-2020: 48.1%) and amounted to KEUR 20,728 compared to KEUR 18,679 (3M-2020). The consolidation of RVC Medical contributed about 5 % to the growth of the NEXUS Group.

The consolidated surplus rose very sharply by 25.8% to KEUR 3,820 (3M-2020: KEUR 3,037), and consolidated earnings before interest and taxes (EBIT) rose by 16.5% to KEUR 5,049 (3M-2020: KEUR 4,335). EBITA increased by 15.4% from KEUR 5,290 (3M-2020) to KEUR 6,105, and EBITDA increased by 7.9% to KEUR 9,086 (3M-2020: KEUR 8,419).



Operative cash flow, which rose from KEUR 20,204 to KEUR 20,489 in the first three months of 2021 (3M-2020: +1.4%), was thus roughly at the same level as in the previous year and remains very high. As of 31/03/2021, the company had cash resources at its disposal in the amount of KEUR 43,804 (31/12/2020: KEUR 28,177). Nexus AG had equity capital amounting to KEUR 126,452 as of 31/03/2021 (31/12/2020: KEUR 123,583). Consequently, the equity capital rate is 50.4% (31/12/2020: 55.4%). This demonstrates that Nexus AG has a sustainable and healthy balance sheet as well as sufficient capital for further financing of its European growth strategy.

The detailed Quarterly Report Q1 can be found on our homepage at:  
<https://en-en.nexus-ag.de/company/investor-relations>

## About Nexus AG

Nexus AG develops and sells software solutions for the international healthcare market. With our core Hospital Information System (NEXUS / HIS) and integrated diagnostic modules (NEXUS / DIS), we have a unique product range, which can cover almost all functional requirements of hospitals, psychiatric institutions, rehabilitation facilities and diagnostic centers within our own product families. The focus of product development is on easy-to-use process support that increases efficiency and safety in patient treatment. NEXUS employs approx. 1,500 people, is present in seven European countries with its own sites and serves customers in an additional 23 countries via certified dealers. Thanks to continuously growing demand for NEXUS products, we have been able to build up a large customer base in recent years and regularly show increases in sales and results.